Conditions: Phase 1 Sickle Cell
Allocation: RANDOMIZED | Intervention model: 
Enrollment: 30
Healthy volunteers: no

Brief summary:
This study is being conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational drug, PF-04447943, in subjects with stable sickle cell disease with and without co-administration with hydroxyurea. This study will also aid in selecting the doses for future studies and evaluation of substances in the blood which may help access the effectiveness of the drug.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: PDE9i intervention 2: PDE9i intervention 3: placebo for PDE9i intervention 4: PDE9i
Intervention descriptions: intervention 1: oral dose, every 12 hours for 28 days intervention 2: oral dose, every 12 hours for 28 days intervention 3: oral dose, every 12 hours for 28 days intervention 4: oral dose, every 12 hours for 28 days

Protocol document: